Monoclonal antibody purification process.

BACKGROUND OF THE INVENTION

0001This invention relates to a process for purifying monoclonal antibodies. In one of its more particular aspects this invention relates to the purification of mammalian derived immunoglobulins.

0002With the discovery of techniques for the preparation of monoclonal antibodies derived from mammals, particularly mouse monoclonal antibodies, the need has arisen for purification of such monoclonal antibodies. Conventional purification techniques in which mixtures containing either polyclonal or mono­clonal antibodies are passed through a suitable column to selectively adsorb the antibody from the mixture and the absorbed antibody is later eluted from the column in purified form have been used for this purpose. However, the yield and purity of the isolated antibodies which can be obtained is limited by the lack of specificity of the column.

0003Previous processes for the purification of immunoglobulins, for example, suffered from the rela­tively low specificity of the absorbent for the im­munoglobulin. In one such process, various fractions of immunoglobulins from sera of different mammalian species were adsorbed upon protein A-Sepharose® adsorbents at pH 7 or higher and eluted at pH's ranging from pH 2.5 to pH 6.5. [R. Lindmark, K. Thoren-Tolling and J. Sjoquist, "Binding of Immunoglobulins to Protein A and Im­munoglobulin Levels in Mammalian Sera," <u style="single">Journal of Immunological Methods</u>, 62:1 (1983)]. It was also known that binding of mouse IgG to protein A-Sepharose® is pH sensitive and that optimum adsorption occurs using 0.1 M sodium phosphate, pH 8.0 buffer. [P. L. Ey, S. J. Prowse and C. R. Jenkin, "Isolation of Pure IgG₁, IgG_2a and IgG_2b Immunoglobulins From Mouse Serum Using Protein A-Sepharose," <u style="single">Immunochemistry</u>, 15:429 (1978)].

0004Recently, efforts have been made to increase the recovery of various immunoglobulins using specially formulated buffers. ["Mouse Monoclonal IgG₁, Purifica­tion with Affi-Gel® Protein-A, "<u style="single">Bulletin 1172, Bio-Rad Laboratories</u>, Bio-Rad Chemical Division, Richmond, California (1984)].

0005It would be desirable to provide a purifica­tion process which would result in still higher yields of immunoglobulins.

0006Accordingly, it is an object of the present invention to provide an improved process for the purification of monoclonal antibodies and particularly immunoglobulins obtained from mammals.

0007It is another object of the present invention to provide such a process which does not require additional purification steps.

0008Another object of the present invention is to provide a rapid, convenient and economically practical process for improving the yield of monoclonal or polyclonal antibody realized in the adsorption thereof.

0009Other objects and advantages of this invention will become apparent from the following detailed disclosure.

SUMMARY OF THE INVENTION

0010The present invention provides a process for the purification of monoclonal and polyclonal anti­bodies, such as immunoglobulins, which is characterized by higher yields than have previously been realizable. The process includes the steps of mixing a medium containing immunoglobulins with a buffer solution having a pH in the range of about pH 7.5 to pH 10 which contains a hydrophobic interaction-promoting salt in the form of a combination of monovalent cations and poly­basic anions in a concentration of about 0.6M to 1.75M to provide a buffered immunoglobulin medium, contacting the resulting buffered immunoglobulin medium with an immobilized protein A adsorbent to adsorb the im­munoglobulins present in the buffered immunoglobulin medium upon the immobilized protein A adsorbent, washing the immobilized protein A adsorbent having im­munoglobulins adsorbed thereon with the buffer solution, contacting the immobilized protein A adsorbent having immunoglobulins adsorbed thereon with a buffer solution having a pH in the range of about pH 3 to pH 6 to remove the adsorbed immunoglobulins from the immobilized protein A adsorbent, and recovering the removed immuno­globulins in substantially pure form. The yield of immunoglobulins realized according to the process of the present invention is increased by about twenty percent (20%) to more than ninety percent (90%) over yields previously obtainable.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

0011The process of the present invention is useful in purifying immunoglobulins of various types including both monoclonal and polyclonal antibodies. It is applicable to many IgG subclasses such as IgG₁, IgG_2a, IgG_2b and others. Antibodies from a wide variety of hosts including mouse, gerbil, rabbit, goat, horse, cow; and human antibodies can be purified using the process of the present invention. In general, it is applicable to any immunoglobulin for which protein A has a reason­able affinity. Immunoglobulins can be obtained from normal or immune mammalian serum, mammalian plasma, ascites fluid, hybridomas, tissue culture fluid, or any other source of antibodies.

0012The process of the present invention utilizes as an adsorbent an immobilized protein A. Although it is known that protein A interacts with various immuno­globulins, principally IgG from mammalian species, in the purified soluble state or as formalin-fixed S. aureus bacteria containing protein A, the use of protein A in other than an insolubilized state is not as practical as the utilization of, for example, protein A immobilized upon a cross-linked agarose. Protein A in its insolubilized form can conveniently be used in a column, which facilitates conducting the purification process.

0013Many suitable immobilized protein A adsorbents are commercially available. A purified protein A coupled to cross-linked agarose beads by chemically stable amide bonds can be obtained from Bio-Rad Labora­tories, Richmond, California as Affi-Gel® Protein A. Protein A-Agarose is also available from Zymed Labo­ratories, Burlingame, California. This product is described as a pure protein A coupled to CNBr-activated Sepharose® 4B. A similar product, Protein A Sepharose ® CL-4B is also available from Pharmacia Fine Chemicals, Uppsala, Sweden. Protein A-Ultrogel® is available from Reactifs IBF, France. It is described as a biospecific affinity chromatography sorbent able to interact with different immunoglobulins G from different mammals and is prepared by immobilizing electrophoretically pure protein A to a glutaraldehyde-activated gel. Protein A covalently coupled to cross-linked beaded agarose is also available from Pierce Chemical Co.

0014An immobilized protein A can also be provided using the techniques disclosed in U.S. Patent No. 4,582,875, assigned to the same assignee as the present invention, the disclosure of which is hereby incorpo­rated by reference. This patent generally teaches the activation of hydroxyl group-containing polymeric carriers using 2-fluoro-1-methylpyridinium toluene-4-­sulfonate (FMP). Such activated polymers are commer­cially available from BioProbe International, Inc., Tustin, California. Avid-Gel™ FMP-activated hydro­philic gel is an FMP-activated polymer of N-acryloyl-2-­amino-2-hydroxymethyl-1,3-propanediol (Trisacryl GF 2000, Reactifs IBF, France). Avid-Gel F™ FMP-activated hydrophilic gel is an FMP-activated hydrophilic vinyl alcohol polymer composed exclusively of C, H and O atoms (Fractogel TSK, E. Merck, Darmstadt, Germany). Both can be used to provide an immobilized protein A.

0015The first step in the process of the present invention requires a buffer having a pH in the range of about pH 7.5 to pH 10 and a combination of monovalent cations and polybasic anions in a concentration of about 0.6 M to 1.75 M. Any buffer may be used to provide the desired pH. For example glycine buffer, borate buffer or tris buffer can be used. The concentration of buffer should be in the range of about 0.01M to 0.25M.

0016Where the monovalent cations are potassium ions and the polybasic anions are phosphate ions the potassium ions and phosphate ions can be provided by the use of potassium phosphate either in the form of tripotassium phosphate, K₃PO₄, dipotassium hydrogen phosphate, K₂HPO₄ or monopotassium dihydrogen phosphate, KH₂PO₄, since the pH of the medium controls the propor­tion of the various phosphate ions which are present. The potassium ions and phosphate ions should be present in a concentration in the range of about 0.6 M to 1.75M. A concentration of about 1.0M to 1.5M has been found especially satisfactory.

0017Other combinations of monovalent cations and polybasic anions which have adequate solubilities at the high concentrations used in the present invention, include ammonium phosphates in concentrations of about 1.0M to 1.5M, ammonium sulfates in concentrations of about 1.0M to 1.5M and sodium sulfates in concentrations of about 1.0M to 1.25M. Other combinations may be used as well so long as the salts do not precipitate at the concentrations used.

0018As pointed out above, the adsorbent is preferably used in a column to facilitate contact with the immunoglobulins to be purified. Prior to applica­tion of the medium containing the impure immunoglobulins to the column, the column is equilibrated with several bed volumes of buffer containing the combination of to the column, the column is equilibrated with several bed volumes of buffer containing the combination of monovalent cations and polybasic anions at concentra­tions in the range of about 0.6M to 1.75M. This ensures that the environment is optimum for binding the im­munoglobulins to the column. The medium containing the immunoglobulins to be purified, such as an immune serum or other source of immunoglobulins is mixed with the buffer containing the combination of monovalent cations and polybasic anions. The resulting mixture is then applied to the column, resulting in adsorption of the immunoglobulins to the column. The column is then washed with additional buffer containing the combination of monovalent cations and polybasic anions in order to elute from the column impurities which are not strongly adsorbed to the column. The immunoglobulins on the other hand are strongly adsorbed to the column because of the enhanced affinity of the adsorbent for the immunoglobulins as a result of the presence of the buffer containing the combination of monovalent cations and polybasic anions. Following removal of the un­desired impurities by washing with the same buffer solution, the purified immunoglobulins are eluted from the column by means of a buffer having an acidic pH, namely a pH in the range of about pH 3.0 to pH 6.0. At pH 6.0 a part of the immunoglobulins, principally the IgG₁ fraction, is eluted. As the pH is lowered the remainder of the immunoglobulins, including the IgG_2a and IgG_2b fractions, is eluted. The immunoglobulins can be eluted using a pH 3.0 buffer, which is effective to elute all of the immunoglobulins. However, if desired, a fraction of the immunoglobulins can be eluted at pH 6.0. Various other fractions can be eluted, if so desired, by lowering the pH between pH 6.0, and pH 3.0. By lowering the pH in steps, it is possible to isolate purified fractions of immunoglobulins which contain specific immunoglobulins as desired. Any buffer can be used for elution. For example an acetic acid-acetate buffer can be used for this purpose. A buffer concen­tration in the range of about 0.1M to 0.25M can be used. A buffer concentration of about 0.05M to 0.10M is especially preferred.

0019The isolated immunoglobulins or fractions thereof can be recovered in yields which are as much as ninety percent (90%) higher than yields previously obtainable. Even yields obtained using the most sophisticated techniques previously available can be improved by as much as twenty to thirty percent (20-­30%).

0020The invention will be better understood by reference to the following examples which are intended for purposes of illustration and are not to be construed as in any way limiting the scope of the present inven­tion which is defined in the claims appended hereto.

<u style="single">EXAMPLE 1</u>

0021To a 3 ml column was added 1 ml of immobilized protein A (Protein A Avid Gel™, BioProbe International, Inc. Tustin, California). The column was equilibrated with 10 ml of a 0.025 M glycine buffer containing 1.2 M K₂HPO₄. The pH was varied from pH 8.0 to pH 10.0. A quantity of 1 ml of normal mouse serum (from Granite Diagnostics, Burlington, North Carolina) was diluted with 1 ml of buffer and applied to the column. Then the column was washed with 5-10 ml of buffer. The immuno­globulins which were adsorbed on the column were eluted with 5 ml of 0.1 M acetic acid, sodium acetate buffer, pH 3.5. The yields of immunoglobulins obtained ranged from eighty percent (80%) to one hundred percent (100%) in the pH range of pH 8.0 to pH 10.0, the yields increasing with pH. By comparison, use of a phosphate buffered saline (PBS), pH 9.0 resulted in a yield of only twenty percent (20%).

<u style="single">EXAMPLE 2</u>

0022To a 3 ml column was added 1 ml of immobilized protein A (Affi- Gel® Protein A, Bio-Rad Laboratories, Richmond, California). The column was equilibrated with 10 ml of a 0.025 M glycine, pH 9.1 buffer containing 1.2 M K₂HPO₄. A quantity of 1 ml of normal mouse serum (from Pel-Freez Biological, Rogers, Arkansas) was diluted with 1 ml of buffer and applied to the column. Then the column was washed with 5-10 ml of buffer. The immunoglobulins contained in the serum sample were eluted from the column with 5 ml of 0.1 M acetic acid sodium acetate buffer, pH 3.5 in a yield of 13.8 mg. This yield was twenty percent (20%) higher than was obtained using a commercially available buffer solution (Affi-Gel® Protein A MAPS Buffer, Bio-Rad Laboratories, Richmond, California).

<u style="single">EXAMPLE 3</u>

0023To a 3 ml column was added 1 ml of immobolized Protein A (Protein A Avid Gel™, BioProbe International, Inc., Tustin, California). The column was equilibrated with 10 ml of a 0.025 M glycine, 0.025M sodium borate buffer, pH 9.1, containing varying concentrations of K₂HPO₄ as shown in Table 1. A quantity of 1 ml of normal mouse serum (obtained from Pel-Freez Biological, Rogers, Arkansas) was diluted with 1 ml of buffer and applied to the column. Then the column was washed with 5-10 ml of buffer. The immunoglobulins adsorbed on the column were eluted with 5 ml of 0.1 M acetic acid-sodium acetate buffer, pH 3.5. The yields of immunoglobulins obtained are shown in Table 1. <tables id="tabl0001" num="0001"><table frame="all"><title>TABLE I</title><tgroup cols="2" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="78.75mm" /><colspec colnum="2" colname="col2" colwidth="78.75mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center"><b>K₂HPO₄ CONCENTRATION (M)</b></entry><entry namest="col2" nameend="col2" align="center"><b>YIELD OF IMMUNOGLOBULINS (mg.)</b></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="char" char=".">0.6</entry><entry namest="col2" nameend="col2" align="char" char=".">11.0</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">0.8</entry><entry namest="col2" nameend="col2" align="char" char=".">13.1</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">1.0</entry><entry namest="col2" nameend="col2" align="char" char=".">13.5</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="char" char=".">1.2</entry><entry namest="col2" nameend="col2" align="char" char=".">14.5</entry></row></tbody></tgroup></table></tables> Much higher concentration of K₂HPO₄ resulted in precipi­tation of the immunoglobulins.

<u style="single">EXAMPLE 4</u>

0024To a 3 ml column was added 1 ml of immobilized protein A (Protein A Avid Gel ™, BioProbe Internation­al, Inc., Tustin, California). The column was equi­librated with 10 ml of 0.1M glycine, 0.1M sodium borate, 0.1M sodium phosphate buffer, pH 9.1, containing varying concentrations of K₂HPO₄ as shown in Table 2. A quantity of 1 ml of mouse monoclonal antibody to rat Kappa chain from ascites fluid was diluted with 1 ml of the buffer and applied to the column. The ascites fluid was obtained as follows. BALB/c mice were immunized by injection or purified rat Kappa chain emulsified with complete Freund's adjuvant. Spleens from immunized mice were moved aseptically and minced with tweezers. Mouse myeloma RG 11-15 cells were fused with spleen cells from immunized mice by using fifty percent (50%) poly(ethylene glycol). After the selection in HAT medium and screening for the hybridoma clones that secrete antibody, the hybridoma cells were injected intraperitoneally into BALB/c mice that have been irradiated with 500 rad gamma-ray. Ascites fluid harvested was clarified by low-speed centrifugation and purified by using immobilized protein A. Following application of the monoclonal antibody the column was washed with 5-10 ml of the same buffer. The immuno­globulins which were adsorbed on the immobilized Protein A were eluted with 5 ml of 0.1M acetic acid sodium acetate buffer, pH 3.5. The yield of immunoglobulins obtained are shown in Table 2. For comparison, the immunoglobulin yields obtained by using MAPS buffer and phosphate buffered saline with 2M NaCl are also shown in Table 2. <tables id="tabl0002" num="0002"><table frame="all"><title>TABLE 2</title><tgroup cols="2" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="78.75mm" /><colspec colnum="2" colname="col2" colwidth="78.75mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center"><b>POTASSIUM PHOSPHATE (M)</b></entry><entry namest="col2" nameend="col2" align="center"><b>YIELD OF IMMUNOGLOBULINS (mg.)</b></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">0.5</entry><entry namest="col2" nameend="col2" align="char" char=".">1.3</entry></row><row><entry namest="col1" nameend="col1" align="left">0.75</entry><entry namest="col2" nameend="col2" align="char" char=".">2.4</entry></row><row><entry namest="col1" nameend="col1" align="left">1.0</entry><entry namest="col2" nameend="col2" align="char" char=".">3.3</entry></row><row><entry namest="col1" nameend="col1" align="left">1.25</entry><entry namest="col2" nameend="col2" align="char" char=".">4.8</entry></row><row><entry namest="col1" nameend="col1" align="left">1.50</entry><entry namest="col2" nameend="col2" align="char" char=".">5.3</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">1.75</entry><entry namest="col2" nameend="col2" align="char" char=".">6.0</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left"><b>MAPS Buffer</b></entry><entry namest="col2" nameend="col2" align="char" char=".">3.1</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left"><b>Phosphate Buffered Saline with 2M NaCl</b></entry><entry namest="col2" nameend="col2" align="char" char=".">1.2</entry></row></tbody></tgroup></table></tables>

<u style="single">EXAMPLE 5</u>

0025To a 3 ml column was added 1 ml of immobilized protein A (Protein A Avid-Gel™, BioProbe International, Inc., Tustin, California). The column was equilibrated with 10 ml of a 0.05 M Tris (hydroxymethyl) amino­methane (Tris) buffer, pH 8.5, containing 1.0 M K₂HPO₄. A quantity of 1 ml of mouse monoclonal antibody from ascites fluid was diluted with 1 ml of buffer and applied to the column. Then the column was washed with 5-10 ml of buffer. The immunoglobulins which were adsorbed on the column were eluted with 5 ml of 0.1 M acetic acid-sodium acetate buffer, pH 3.5. The yield of immunoglobulins obtained was 2.9 mg.

<u style="single">EXAMPLE 6</u>

0026The procedure of Example 5 was followed except that the buffer used was a 0.25 M glycine, 0.1 M Tris buffer, pH 8.9, containing 1.5 M K₂HPO₄. The yield of immunoglobulins obtained was 4.49 mg.

<u style="single">EXAMPLE 7</u>

0027To a 3 ml. column was added 1 ml. of immobil­ized protein A (Protein A Avid-Gel ™, BioProbe Interna­tional, Inc., Tustin, California). The column was equilibrated with 10 ml. of a 0.1 M Tris (hydroxymethyl) aminomethane buffer, the pH varying as shown in Table 3, which contained varying concentrations of hydrophobic interaction-promoting salts, as shown in Table 3. A quantity of 3 ml. human immunoglobulin solution and 6 ml. of the above buffer mixture were well mixed and applied to the column. Then the column was washed with 10 ml. buffer. The bound immunoglobulins were eluted from the column with 10 ml. of 0.1 M acetic acid-sodium acetate buffer, pH 3.5. The quantity of immunoglobulins in the elute was determined by measuring the absorbance of the elute solution at 280 nm. The results are shown in Table 3. <tables id="tabl0003" num="0003"><table frame="all"><title>TABLE 3</title><tgroup cols="4" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="39.37mm" /><colspec colnum="2" colname="col2" colwidth="39.37mm" /><colspec colnum="3" colname="col3" colwidth="39.37mm" /><colspec colnum="4" colname="col4" colwidth="39.37mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Salt</entry><entry namest="col2" nameend="col2" align="center">pH</entry><entry namest="col3" nameend="col3" align="center">Concentration M</entry><entry namest="col4" nameend="col4" align="center">Quantity of Immunoglobulins in Eluate, mg.</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Ammonium Phosphate</entry><entry namest="col2" nameend="col2" align="char" char=".">7.5</entry><entry namest="col3" nameend="col3" align="char" char=".">0.0</entry><entry namest="col4" nameend="col4" align="char" char=".">22.1</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">0.5</entry><entry namest="col4" nameend="col4" align="char" char=".">18.8</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">1.0</entry><entry namest="col4" nameend="col4" align="char" char=".">23.6</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">1.5</entry><entry namest="col4" nameend="col4" align="char" char=".">28.4</entry></row><row><entry namest="col1" nameend="col1" align="left">Ammonium Sulfate</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">0.0</entry><entry namest="col4" nameend="col4" align="char" char=".">22.1</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">0.5</entry><entry namest="col4" nameend="col4" align="char" char=".">20.5</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">1.0</entry><entry namest="col4" nameend="col4" align="char" char=".">23.0</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">1.5</entry><entry namest="col4" nameend="col4" align="char" char=".">35.2</entry></row><row><entry namest="col1" nameend="col1" align="left">Sodium Sulfate</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">0.0</entry><entry namest="col4" nameend="col4" align="char" char=".">22.1</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">0.5</entry><entry namest="col4" nameend="col4" align="char" char=".">21.7</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">1.0</entry><entry namest="col4" nameend="col4" align="char" char=".">34.8</entry></row><row><entry namest="col1" nameend="col1" align="left">Ammonium Phosphate</entry><entry namest="col2" nameend="col2" align="char" char=".">8.5</entry><entry namest="col3" nameend="col3" align="char" char=".">0.0</entry><entry namest="col4" nameend="col4" align="char" char=".">19.1</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">0.5</entry><entry namest="col4" nameend="col4" align="char" char=".">13.1</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">1.0</entry><entry namest="col4" nameend="col4" align="char" char=".">19.8</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">1.5</entry><entry namest="col4" nameend="col4" align="char" char=".">27.3</entry></row><row><entry namest="col1" nameend="col1" align="left">Sodium Sulfate</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">0.0</entry><entry namest="col4" nameend="col4" align="char" char=".">19.1</entry></row><row><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">0.5</entry><entry namest="col4" nameend="col4" align="char" char=".">16.7</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">"</entry><entry namest="col2" nameend="col2" align="char" char=".">"</entry><entry namest="col3" nameend="col3" align="char" char=".">1.0</entry><entry namest="col4" nameend="col4" align="char" char=".">24.0</entry></row></tbody></tgroup></table></tables>

0028The present invention provides an improved process for the purification of immunoglobulins which is rapid and convenient. Yields of immunoglobulins improved by twenty to over ninety percent (20-90%) over previous methods are realizable by practicing the process of the present invention.

0029The foregoing description of the invention has been directed to particular preferred embodiments for purposes of explanation and illustration. It will be apparent, however, to those skilled in the art, that many modifications and changes in the particular methods and materials may be made without departure from the scope and spirit of the invention. For example, the adsorption process can be carried out in a batchwise manner or in other buffered solutions. It is appli­cant's intention in the following claims to cover all such equivalents, modifications and changes that fall within the true spirit and scope of the invention.